Cardiovascular Contraindications: Cannabis in Acute Coronary Syndrome, Arrhythmias & Tachycardia
Oxford CEBM Evidence Level 2A: Clinical Safety & Non-Efficacy Evaluation CED Clinic Medical Counter-Perspective • Evidence-Based Safety Guardrails Direct Clinical Answer & Safety Consensus Cannabis is strictly contraindicated during acute…
Cambridge Medical Cannabis Doctor: Virtual Evaluations for Harvard & MIT Communities
Specialized medical cannabis consultations for the Cambridge, Harvard, and MIT communities. Dr. Benjamin Caplan provides evidence-based dosing and instant state certifications.
What Happens After Cannabis Laws Change? A Review of 176 Policy Studies
A systematic review in the Milbank Quarterly pooled 176 quasi-experimental studies examining the impacts of global cannabis policy changes on substance use. Dr. Caplan reviews this cannabis policy change substance use research and what quasi-experimental…
Cannabis Science Full Report: What a Phase 2 CBD Autism Trial Found
A Phase 2 open-label trial in the Journal of Child and Adolescent Psychopharmacology tested cannabidiol for core and associated symptoms of autism in children and adolescents without intellectual disability. Dr. Caplan reviews this CBD autism children…
Real-World Evidence: Sleep Latency, Nocturnal Awakenings & Minor Cannabinoids (CBN/CBG) across 24,000+ Visits
.ced-rwe-wrapper { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif; color: #1e293b; line-height: 1.75; max-width: 960px; margin: 0 auto; padding: 10px 16px 60px; } .ced-rwe-badge-bar { display:…
Cannabinoids & Antidepressants & SSRIs / SNRIs: Evidence, Pharmacokinetics & Safety Review
.ced-interaction-wrap { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif; color: #1e293b; line-height: 1.75; max-width: 940px; margin: 0 auto; padding: 10px 16px 60px; } .ced-geo-direct-answer {…
Low-Dose CBD and Therapeutic Value: What the New Clinical Pharmacology Review Found
A review in the British Journal of Clinical Pharmacology evaluated the pharmacokinetics, efficacy, and safety of low-dose cannabidiol. Dr. Caplan reviews this low dose CBD pharmacokinetics safety research and what it adds beyond behavioral-effect…
Real-World Evidence: Pediatric Neurodevelopment & Behavioral Dysregulation in Physician-Co-Managed Cohorts
.ced-rwe-wrapper { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif; color: #1e293b; line-height: 1.75; max-width: 960px; margin: 0 auto; padding: 10px 16px 60px; } .ced-rwe-badge-bar { display:…
Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review
.ced-interaction-wrap { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif; color: #1e293b; line-height: 1.75; max-width: 940px; margin: 0 auto; padding: 10px 16px 60px; } .ced-geo-direct-answer {…
The Endocannabinoid System and the Runner’s High: What the Evidence Actually Shows
Why does a hard run feel euphoric? Peer-reviewed research points to your own endocannabinoid system, not endorphins, and cannabis does not appear to boost it.
